Novartis's QVA149 indacaterol maleate/glycopyrronium DPI demonstrated 15% greater reduction in all COPD exacerbations compared to glycopyrronium and 14% compared to tiotropium according to study results published April 23 2013 in Lancet Respiratory Medicine. QVA149 reduced moderate-to-severe exacerbations by 12% over glycopyrronium. The study also showed improved lung … [Read more...] about QVA149 data demonstrates superior reduction of COPD exacerbations compared to glycopyrronium alone
News
Anoro Ellipta application submitted in Japan
GlaxoSmithKline and Theravance have submitted an application for the Anoro Ellipta umeclidinium bromide /vilanterol (UMEC/VI) DPI for the treatment of COPD to the Japanese Ministry of Health, Labour and Welfare (MHLW), the companies said. The submission in Japan is for 62.5/25mcg and 125/25mcg doses of UMEC/VI. In the US, the Anoro Ellipta has a PDUFA date of … [Read more...] about Anoro Ellipta application submitted in Japan
GW receives Notice of Allowance for patent on spray device
GW Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance in response to its patent application for a metered dose spray device for sublingual delivery of Sativex liquid cannabis extract formulation. The application serial number is 13/606,742. GW CEO Justin Gover commented, “This Notice of … [Read more...] about GW receives Notice of Allowance for patent on spray device
Doug Millington-Smith joins Freeman Technology
Powder characterization specialist Freeman Technology has hired Doug Millington-Smith as Applications Specialist at the company's UK headquarters. As Applications Specialist, he will support users of the company's FT4 Powder Rheometer, which is used for characterization of powders for a wide variety of uses, including inhalation. Managing Director Tim Freeman … [Read more...] about Doug Millington-Smith joins Freeman Technology
Argenta to supply respiratory drug discovery services to BI
Galapagos subsidiary Argenta has signed an agreement with Boehringer Ingelheim to provide respiratory drug discovery services for "an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio," the company said. On its website, Argenta says that it generally expects nomination of a respiratory drug candidate within 2 years and has nominated 16 … [Read more...] about Argenta to supply respiratory drug discovery services to BI
Positive Phase 2 results for inhaled L-dopa
In a Phase 2 study of Civitas Therapeutics' CVT-301 inhaled levodopa (L-dopa), Parkinson's disease patients with motor fluctuations (OFF episodes) who used the drug experienced "rapid and durable" motor function improvement, the company announced. The 24-patient randomized, placebo-controlled study was funded in part by a grant from the Michael J. Fox Foundation. … [Read more...] about Positive Phase 2 results for inhaled L-dopa
Impel Neuropharma SPECT imaging study shows nose-to-brain delivery
According to Impel NeuroPharma, the results of a human proof of concept study using SPECT imaging demonstrated nose-to-brain delivery by its Precision Olfactory Delivery (POD) device. The company said that the SPECT images showed deposition of radiolabeled tripeptide by the POD device in the deep nasal cavity and bypassing of the blood brain barrier with delivery to … [Read more...] about Impel Neuropharma SPECT imaging study shows nose-to-brain delivery
SNBL licenses intranasal delivery system to Besins for intranasal progesterone
Besins Healthcare will license the Muco (μco) intranasal system from Shin Nippon Biomedical Laboratories (SNBL) for delivery of its BHR-310 progesterone powder, which it is developing for the treatment of mild traumatic brain injury (TBI). The SNBL system includes a muco-adhesive drug carrier and a delivery device called the Fit-Lizer. Besins Chief Development … [Read more...] about SNBL licenses intranasal delivery system to Besins for intranasal progesterone
FDA advisory committee recommends approval of Breo Ellipta
The FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted to recommend approval of of GSK and Theravance's Breo Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of COPD. The PADAC meeting had been rescheduled from an earlier date due to weather. During the rescheduled meeting on April 17, the committee voted in favor of approval … [Read more...] about FDA advisory committee recommends approval of Breo Ellipta
Phase 2 study of Savara’s AeroVanc initated
Savara Pharmaceuticals has announced the commencement of a Phase 2 clinical trial of its AeroVanc inhaled dry powder vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The randomized, double-blind, placebo-controlled study will involve 80 CF patients across the US. Results should be available … [Read more...] about Phase 2 study of Savara’s AeroVanc initated